import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "ozempic-mounjaro-wegovy-research-peptide-comparison",
  title: "Ozempic vs Mounjaro vs Wegovy: What Researchers Need to Know",
  description:
    "A research-focused comparison of the branded GLP-1 and GLP-1/GIP receptor agonists — semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound) — covering mechanisms, preclinical data, and what these mean for peptide research design.",
  category: "Compound Profiles",
  readMinutes: 10,
  publishedAt: "2026-06-05",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Ozempic, Wegovy, and Mounjaro are household names. Behind the brand names are two distinct peptide compounds — semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GLP-1/GIP receptor agonist) — that represent some of the most intensively studied molecules in modern pharmacology. For peptide researchers, understanding the mechanistic differences, preclinical data, and molecular structure of these compounds is foundational context for any incretin-axis study design.",
    },
    {
      type: "paragraph",
      text: "This article covers what these compounds are at the molecular level, how they differ mechanistically, what the preclinical and clinical data show, and what those differences mean for research protocols.",
    },
    {
      type: "heading",
      text: "The Brand Name Landscape",
    },
    {
      type: "table",
      headers: ["Brand Name", "Active Compound", "Approved Indication", "Mechanism"],
      rows: [
        ["Ozempic", "Semaglutide", "Type 2 diabetes (weekly SC)", "GLP-1 agonist"],
        ["Wegovy", "Semaglutide", "Chronic weight management (weekly SC)", "GLP-1 agonist"],
        ["Rybelsus", "Semaglutide", "Type 2 diabetes (oral daily)", "GLP-1 agonist"],
        ["Mounjaro", "Tirzepatide", "Type 2 diabetes (weekly SC)", "GLP-1 + GIP dual agonist"],
        ["Zepbound", "Tirzepatide", "Chronic weight management (weekly SC)", "GLP-1 + GIP dual agonist"],
      ],
    },
    {
      type: "paragraph",
      text: "From a research perspective, the brand names are irrelevant — what matters is the molecular compound: semaglutide or tirzepatide. The research-grade analogs used in preclinical studies are structurally equivalent to these FDA-approved drugs, allowing researchers to model the same mechanistic pathways.",
    },
    {
      type: "heading",
      text: "Semaglutide: The GLP-1 Receptor Agonist",
    },
    {
      type: "subheading",
      text: "Molecular Structure",
    },
    {
      type: "paragraph",
      text: "Semaglutide is a 31-amino acid peptide analog of native human GLP-1 (glucagon-like peptide-1), sharing approximately 94% amino acid homology with the endogenous hormone. Two key structural modifications distinguish it from native GLP-1: a substitution at position 8 (Aib replaces Ala, conferring DPP-4 resistance) and a C18 fatty diacid chain attached via a linker at lysine-26, which promotes albumin binding and dramatically extends plasma half-life from ~2 minutes (native GLP-1) to approximately 7 days.",
    },
    {
      type: "subheading",
      text: "Primary Mechanism",
    },
    {
      type: "list",
      items: [
        "GLP-1 receptor (GLP-1R) agonism — a G-protein coupled receptor expressed in pancreatic beta cells, gut, brain, heart, and kidney",
        "Glucose-dependent insulin secretion — stimulates insulin release only when blood glucose is elevated (low hypoglycemia risk)",
        "Glucagon suppression — reduces hepatic glucose output in the postprandial state",
        "Gastric emptying delay — slows nutrient absorption, contributing to satiety and post-meal glucose blunting",
        "Central appetite suppression — GLP-1R activation in hypothalamic arcuate nucleus and brainstem reward circuits reduces food intake",
      ],
    },
    {
      type: "subheading",
      text: "Key Preclinical Research Findings",
    },
    {
      type: "paragraph",
      text: "Preclinical models of semaglutide have documented effects beyond glycemic control. In rodent obesity models, GLP-1R agonism reduces body weight by 15–25% through combined caloric restriction and metabolic effects. Neurological data show neuroprotective properties in models of Parkinson's disease (α-synuclein clearance), Alzheimer's disease (amyloid-β reduction), and stroke (reduced infarct volume). Cardiac studies demonstrate reduced atherosclerosis progression and improved outcomes in MI models, consistent with the SELECT trial's cardiovascular mortality data in humans.",
    },
    {
      type: "heading",
      text: "Tirzepatide: The Dual GLP-1/GIP Receptor Agonist",
    },
    {
      type: "subheading",
      text: "Molecular Structure",
    },
    {
      type: "paragraph",
      text: "Tirzepatide is a 39-amino acid synthetic peptide based on the native GIP (glucose-dependent insulinotropic polypeptide) sequence, engineered to also activate GLP-1 receptors. Its C20 fatty diacid chain (via a gamma-glutamic acid linker) provides equivalent albumin binding and ~5-day half-life. The dual-agonist architecture distinguishes it fundamentally from semaglutide: it engages both the GIP receptor (GIPR) and GLP-1R simultaneously with near-equipotent affinity at each.",
    },
    {
      type: "subheading",
      text: "GIP Receptor Contribution",
    },
    {
      type: "paragraph",
      text: "GIP is the other major incretin — secreted by K-cells in the duodenum and jejunum in response to fat and carbohydrate ingestion. At the GIPR, tirzepatide drives several effects not produced by GLP-1R agonism alone:",
    },
    {
      type: "list",
      items: [
        "Enhanced insulin secretion synergy — GIP and GLP-1 pathways are additive on pancreatic beta cell cAMP signaling",
        "Adipose tissue lipid handling — GIPR activation in adipocytes modulates fat storage and mobilization, distinct from GLP-1R fat mass effects",
        "Reduced GI side effects — paradoxically, GIPR co-activation appears to attenuate nausea compared to GLP-1R agonism alone at equivalent metabolic efficacy",
        "Central appetite circuits — GIPR is expressed in the hypothalamus and may contribute to satiety signaling through a distinct pathway from GLP-1R",
      ],
    },
    {
      type: "heading",
      text: "Head-to-Head: Semaglutide vs Tirzepatide in Research Models",
    },
    {
      type: "subheading",
      text: "Weight Loss Efficacy",
    },
    {
      type: "paragraph",
      text: "In DIO (diet-induced obesity) mouse models, tirzepatide consistently outperforms semaglutide at equivalent doses for body weight reduction. The SURMOUNT-1 trial in humans confirmed this: tirzepatide 15mg produced ~22% mean body weight loss vs ~15% for semaglutide 2.4mg (Wegovy dose). The mechanism behind tirzepatide's superior weight loss is still being studied — leading hypotheses include GIPR-mediated adipose lipid mobilization and enhanced hypothalamic appetite suppression via dual receptor engagement.",
    },
    {
      type: "subheading",
      text: "Glycemic Control",
    },
    {
      type: "paragraph",
      text: "Tirzepatide also shows superior HbA1c reduction in T2D models and clinical trials. In SURPASS trials, tirzepatide 15mg reduced HbA1c by ~2.4% vs ~1.9% for semaglutide 1mg. Both compounds produce robust glycemic effects, but the dual incretin mechanism of tirzepatide provides additive insulin secretion stimulation.",
    },
    {
      type: "subheading",
      text: "Cardiovascular Effects",
    },
    {
      type: "paragraph",
      text: "Semaglutide's cardiovascular benefit is well-established — the SUSTAIN-6 and SELECT trials demonstrated reduced MACE (major adverse cardiovascular events) including CV death, non-fatal MI, and non-fatal stroke. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Preclinical cardiac data suggest both compounds improve cardiac function in obesity-related heart disease models, though mechanisms differ: GLP-1R directly modulates cardiomyocyte function and inflammation, while GIPR effects on cardiac outcomes are less characterized.",
    },
    {
      type: "heading",
      text: "Research Design Considerations",
    },
    {
      type: "paragraph",
      text: "For researchers designing studies using semaglutide or tirzepatide analogs, several considerations apply:",
    },
    {
      type: "list",
      items: [
        "Receptor selectivity: When studying GLP-1R-specific effects, semaglutide provides a cleaner tool; tirzepatide always engages both GIPR and GLP-1R — use receptor-specific antagonists as controls when using tirzepatide",
        "Dose selection: Translating human clinical doses to rodent models requires allometric scaling (approximately 10–20× higher mg/kg doses in mice vs humans)",
        "Tachyphylaxis: Both compounds can produce receptor downregulation with chronic dosing — study design should account for tolerance at extended timepoints",
        "DPP-4 resistance: Both are engineered for DPP-4 resistance, unlike native GLP-1 — this must be considered when using DPP-4 as a study variable",
        "Species differences: GIPR pharmacology differs between rodents and primates — findings in mouse GIPR models may not fully translate",
      ],
    },
    {
      type: "heading",
      text: "Sourcing for Research",
    },
    {
      type: "paragraph",
      text: "Research-grade semaglutide and tirzepatide are available as research peptides for preclinical study. Unlike the branded pharmaceutical products — which contain excipients, stabilizers, and delivery systems — research-grade analogs are supplied as lyophilized powder requiring reconstitution. Quality verification is critical:",
    },
    {
      type: "list",
      items: [
        "HPLC purity ≥99% — both compounds are complex, longer peptides where impurity profiles matter",
        "Mass spectrometry identity confirmation — verify molecular weight matches the expected sequence",
        "Endotoxin testing (LAL) — particularly important given these compounds' immune-adjacent mechanisms",
        "Cold-chain shipping and storage at ≤-20°C for long-term stability",
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are the brand expressions of two distinct research-grade peptides — a selective GLP-1 receptor agonist and a dual GLP-1/GIP receptor agonist, respectively. Tirzepatide's superior weight loss efficacy in both preclinical and clinical data appears driven by its GIPR co-engagement, though the full mechanistic picture is still being characterized. For researchers, the choice between these compounds as research tools depends on whether the study requires receptor-selective GLP-1R activation or the full dual-incretin engagement that tirzepatide provides.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use. Semaglutide and tirzepatide are FDA-approved prescription medications; their research analogs are supplied for scientific investigation under appropriate research frameworks.",
    },
  ],
};
